918810-27-2

Upstream product

• 17417-09-3 2-fluoro-5-nitrobenzonitrile 
• 75-08-1 ethanethiol 
• 918810-26-1 2-(Ethylthio)-5-nitrobenzonitrile 

Downstream Products

• 918810-28-3 N-(3-cyano-4-(ethylsulfonyl)phenyl)acetamide 
• 918812-59-6 5-amino-2-(ethylsulfonyl)benzonitrile 
• 918812-73-4 3-(aminomethyl)-4-(ethylsulfonyl)aniline 
• 943743-24-6 tert-butyl 5-amino-2-(ethylsulfonyl)benzylcarbamate 
• 943740-37-2 tert-butyl 5-(4-(4-bromophenyl)butanamido)-2-(ethylsulfonyl)benzylcarbamate 
• 943740-38-3 4-(4-(3-((tert-butoxycarbonylamino)methyl)-4-(ethylsulfonyl)phenylamino)-4-oxobutyl)phenylboronic acid 
• 943740-39-4 2-(4-(4-(3-((tert-butoxycarbonylamino)methyl)-4-(ethylsulfonyl)phenylamino)-4-oxobutyl)phenyl)-2-(4-cyanophenylamino)acetic acid 
• 943740-40-7 2-(4-(4-(3-(aminomethyl)-4-(ethylsulfonyl)phenylamino)-4-oxobutyl)phenyl)-2-(4-cyanophenylamino)acetic acid 
• 943740-13-4 4-(4-bromo-2-methylphenyl)-N-(3-cyano-4-(ethylsulfonyl)phenyl)butanamide 
• 943740-14-5 N-(3-cyano-4-(ethylsulfonyl)phenyl)-4-(4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-2-methylphenyl)butanamide 
• 943740-16-7 2-(1-di-tert-butoxycarbonylaminoisoquinolin-6-ylamino)-2-(4-(4-(3-cyano-4-(ethylsulfonyl)phenylamino)-4-oxobutyl)-3-methylphenyl)acetic acid 
• 943740-08-7 4-(4-bromophenyl)-N-(3-cyano-4-(ethylsulfonyl)phenyl)butanamide 
• 943740-09-8 4-(4-(3-cyano-4-(ethylsulfonyl)phenylamino)-4-oxobutyl)phenylboronic acid 
• 943740-10-1 2-(1-di-tert-butoxycarbonylaminoisoquinolin-6-ylamino)-2-(4-(4-(3-cyano-4-(ethylsulfonyl)phenylamino)-4-oxobutyl)phenyl)acetic acid 

Relevant academic research and scientific papers

Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors

On the basis of a crystal structure of a phenylpyrrolidine lead and subsequent molecular modeling results, we designed and synthesized a novel series of macrocyclic FVIIa inhibitors. The optimal 16-membered macrocycle was 60-fold more potent than an acycl

MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention relates generally to novel macrocycles of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, thereof, wherein the variables A, B, L, M, W, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.

2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention relates generally to novel 2-(aryloxy)acetamides of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables W, Y, Z, R7, R8, and R9 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.

Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.